Oasmia Pharmaceutical AB Performance
| OASMYDelisted Stock | USD 0.06 0.00 0.00% |
The company holds a Beta of 3.5, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oasmia Pharmaceutical will likely underperform. Oasmia Pharmaceutical right now holds a risk of 0.0%. Please check Oasmia Pharmaceutical risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to decide if Oasmia Pharmaceutical will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oasmia Pharmaceutical AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Oasmia Pharmaceutical is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 40.1 M | |
| Total Cashflows From Investing Activities | 118.7 M | |
| Free Cash Flow | -179.9 M |
Oasmia |
Oasmia Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 6.00 in Oasmia Pharmaceutical AB on February 4, 2024 and sell it today you would earn a total of 0.00 from holding Oasmia Pharmaceutical AB or generate 0.0% return on investment over 90 days. Oasmia Pharmaceutical AB is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Oasmia, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Oasmia Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oasmia Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Oasmia Pharmaceutical AB, and traders can use it to determine the average amount a Oasmia Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| OASMY |
Based on monthly moving average Oasmia Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oasmia Pharmaceutical by adding Oasmia Pharmaceutical to a well-diversified portfolio.
Oasmia Pharmaceutical Fundamentals Growth
Oasmia Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Oasmia Pharmaceutical, and Oasmia Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oasmia Pink Sheet performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0875 | ||||
| Current Valuation | 6.58 M | ||||
| Shares Outstanding | 179.35 M | ||||
| Price To Book | 0.68 X | ||||
| Price To Sales | 31.16 X | ||||
| Revenue | 26.19 M | ||||
| EBITDA | (97.54 M) | ||||
| Debt To Equity | 0.01 % | ||||
| Cash Flow From Operations | (145.56 M) | ||||
| Total Asset | 594.31 M | ||||
About Oasmia Pharmaceutical Performance
To evaluate Oasmia Pharmaceutical Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Oasmia Pharmaceutical generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Oasmia Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Oasmia Pharmaceutical market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Oasmia's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. Vivesto Ab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 17 people.Things to note about Oasmia Pharmaceutical performance evaluation
Checking the ongoing alerts about Oasmia Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Oasmia Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oasmia Pharmaceutical is not yet fully synchronised with the market data | |
| Oasmia Pharmaceutical has some characteristics of a very speculative penny stock | |
| Oasmia Pharmaceutical has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 26.19 M. Net Loss for the year was (132.72 M) with loss before overhead, payroll, taxes, and interest of (15.25 M). | |
| Oasmia Pharmaceutical generates negative cash flow from operations |
- Analyzing Oasmia Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oasmia Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Oasmia Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oasmia Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oasmia Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oasmia Pharmaceutical's pink sheet. These opinions can provide insight into Oasmia Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Oasmia Pink Sheet
If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |